How does PD-L1 expression predict nivolumab response?

In NSCLC: nivolumab does not use PD-L1 as a predictive biomarker (unlike pembrolizumab). In other tumor types: PD-L1 CPS ≥1 or ≤5 predicts benefit in bladder cancer, gastric cancer, and HNSCC. MSI-H/dMMR is a pan-tumor predictor regardless of PD-L1 expression. High TMB (≥10 mut/Mb) FDA-approved as a biomarker for pembrolizumab.

What tumor types have highest checkpoint inhibitor response rates?

Highest objective response rates: MSI-H/dMMR tumors regardless of histology (30–40% ORR), Merkel cell carcinoma (60%+), melanoma (40–45% for dual PD-1+CTLA4), classical Hodgkin lymphoma (65%+ with PD-1 inhibitors), cutaneous SCC (35–50%). Lowest responders: prostate cancer, microsatellite-stable CRC, pancreatic cancer (<5%).

Nivolumab Response Probability by Tumor Biomarkers

Estimate nivolumab (PD-1 inhibitor) response probability using PD-L1 TPS/CPS, tumor mutational burden (TMB), MSI-H status, and tumor type for treatment decision support.

Use the full interactive calculator below, or

Related Calculators

Pembrolizumab irAE Score

Medical Long-tail

Nivolumab Response Probability by Tumor Biomarkers

Related Calculators

Frequently Asked Questions

How does PD-L1 expression predict nivolumab response?

What tumor types have highest checkpoint inhibitor response rates?